Bristol Myers Squibb shared a post on LinkedIn:
“Science, standards, access: turning MRD into clinical impact.
Last week, BMS hosted the GUIDE.MRD 4th General Assembly in Boudry at the BMS Collaboration Hub – bringing together academia, patient organizations, pharma, hospitals and diagnostics/technology partners to accelerate ctDNA-based minimal residual disease (MRD) testing in solid tumors. Guide.mrd is an IHI public-private consortium advancing ctDNA-based MRD testing in lung, pancreatic and colorectal cancers.
A big thank you to our panelists Anne Kerber, Lidewij Eva Vat (The Synergist.org), Klaus Pantel (Universitätsklinikum Hamburg Eppendorf), Andrew Slatter (Illumina) and Chiara Antoniani (Lung Cancer Europe) as well as to all consortium partners – for the open exchange and continued collaboration. What a productive session with patients in mind. What a fantastic team!”
Other articles about Bristol Myers Squibb on OncoDaily.